Evofem Biosciences, Inc. 8-K

What Happened
Evofem Biosciences, Inc. filed an 8-K disclosing that on July 8, 2026 it entered into a promissory note with HUB Cyber Security, Ltd. (the “Note”) for aggregate original principal of $706,304. The Note bears interest at 12% per annum, compounded monthly, matures 11 months after July 8, 2026 (i.e., June 8, 2027), and the Company received net proceeds of approximately $706,304.

Key Details

• Principal: $706,304; Interest: 12% per year, compounded monthly.
• Fees: $2,000 per week monitoring fee (about $94,000 if outstanding through maturity) plus a one‑time $14,126 administration fee; monitoring and admin fees accrue and are payable at maturity.
• Term & prepayment: Matures 11 months from July 8, 2026; may be prepaid in whole or part at any time without penalty.
• Credit status & covenants: Note is subordinated (junior to other obligations). It includes covenants restricting mergers, sales of substantially all assets, dissolution, major business changes, and certain payments during an Event of Default; HUB’s prior written consent is required for specified transactions.
• Events of default: Typical defaults (missed payments after 3 days, bankruptcy, unresolved judgments, breaches of covenants). Defaults alleged by the Company’s senior noteholder are excluded from Events of Default under this Note. On default, HUB may require redemption in cash of the Note plus accrued fees and interest.

Why It Matters
This filing shows Evofem increased its short‑term debt by about $706K, with a relatively high cash cost (12% interest plus weekly monitoring fees and an admin fee). The covenants and prohibitions could limit the Company’s flexibility for mergers, asset sales or other major corporate actions without HUB’s consent. Because the Note is subordinated and comes due within 11 months, investors should note the added near‑term repayment obligation and the potential cash flow impact from interest and monitoring fees.